Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.37 USD
Change Today -0.0299 / -2.14%
Volume 21.0K
OXGN On Other Exchanges
As of 9:41 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

oxigene inc (OXGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/14 - $2.57
52 Week Low
07/8/15 - $1.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OXIGENE INC (OXGN)

oxigene inc (OXGN) Related Bloomberg News

View More Bloomberg News

oxigene inc (OXGN) Related Businessweek News

No Related Businessweek News Found

oxigene inc (OXGN) Details

OXiGENE, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents to treat cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating gastrointestinal neuroendocrine tumors. The company also develops OXi4503 for patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. OXiGENE, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

13 Employees
Last Reported Date: 03/30/15
Founded in 1988

oxigene inc (OXGN) Top Compensated Officers

Chief Scientific Officer and Director
Total Annual Compensation: $447.2K
Compensation as of Fiscal Year 2014.

oxigene inc (OXGN) Key Developments

OXiGENE, Inc. Appoints Matthew M. Loar as Chief Financial Officer

OXiGENE, Inc. announced that Matthew M. Loar has been appointed Chief Financial Officer. Mr. Loar is a executive with over 20 years of financial and accounting experience in both public and private companies in the biopharmaceutical industry. Mr. Loar most recently was Chief Financial Officer at KineMed, Inc. Previously, Mr. Loar was an independent financial consultant and was CFO at several public companies engaged in clinical drug development, including Neurobiological Technologies, Osteologix, and Genelabs Technologies. He has served on the board of directors of two public biopharmaceutical companies in the San Francisco Bay Area, and has also served as treasurer of the Silicon Valley Chapter of Financial Executives International (FEI).

OXiGENE, Inc. Announces Resignation of Barbara Riching as Chief Financial Officer

On June 3, 2015, Ms. Barbara Riching resigned from her position as Chief Financial Officer of OXiGENE, Inc., effective immediately, to pursue other interests. The company intends to enter into a separation agreement with Ms. Riching in connection with her departure, on terms consistent with her employment agreement with the company.

OXiGENE Receives Guidance from FDA Supporting Phase 3 Trial of Fosbretabulin/Bevacizumab Combination in Platinum-Resistant Ovarian Cancer

OXiGENE, Inc. provided an update on recent discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a proposed Phase 3 trial of fosbretabulin in combination with bevacizumab in patients with platinum-resistant ovarian cancer. FDA agreed with the company's proposal to test the combination anti-vascular regimen of fosbretabulin and bevacizumab directly against chemotherapy using progression-free survival (PFS) as the primary endpoint in a randomized, controlled registration trial. FDA requested inclusion of a third arm, of bevacizumab alone, in the trial to further characterize the efficacy of each individual drug in the combination. OXiGENE intends to submit an application to the FDA for a Special Protocol Assessment (SPA) later 2015. The proposed Phase 3 trial is based on the results of the GOG186I study in which the anti-vascular combination of fosbretabulin and bevacizumab showed statistically significant improvements in PFS compared to bevacizumab alone as defined by the statistical analysis plan. The benefits appeared to be particularly robust in a subset of patients with platinum-resistant disease where a post-hoc subgroup analysis of the study showed that patients who were platinum-resistant had a median PFS of 6.7 months when treated with bevacizumab and fosbretabulin compared to 3.4 months for those receiving bevacizumab alone.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXGN:US $1.37 USD -0.0299

OXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation OXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXIGENE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at